secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2022-08-22T23:59:59+00:00
Accession:  0001193125-22-226123
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva completes acquisition of La Jolla Pharmaceutical for $6.23 per share
-----------------------------------------------------------------------------

- Tender offer accepted 21,703,224 shares (~87.03% of outstanding) at $6.23 per share, no interest.
- Merger completed on August 22, 2022, with La Jolla surviving as wholly-owned subsidiary.
- All outstanding shares (other than Innoviva-Owned and La Jolla-Owned) converted to $6.23 cash per share.
- Series C-1 Preferred Shares converted to cash equal to 1,724.04 times the Merger Consideration.
- Options with exercise price below $6.23 received cash for spread; options at or above $6.23 cancelled for no consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000119312522226123/0001193125-22-226123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000119312522226123/d233621d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-226123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer